CL2021003047A1 - Forma cristalina de bromuro de sofpironio y método para su preparación - Google Patents
Forma cristalina de bromuro de sofpironio y método para su preparaciónInfo
- Publication number
- CL2021003047A1 CL2021003047A1 CL2021003047A CL2021003047A CL2021003047A1 CL 2021003047 A1 CL2021003047 A1 CL 2021003047A1 CL 2021003047 A CL2021003047 A CL 2021003047A CL 2021003047 A CL2021003047 A CL 2021003047A CL 2021003047 A1 CL2021003047 A1 CL 2021003047A1
- Authority
- CL
- Chile
- Prior art keywords
- sophironium
- bromide
- crystalline form
- preparation
- diastereomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851880P | 2019-05-23 | 2019-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003047A1 true CL2021003047A1 (es) | 2022-09-20 |
Family
ID=72146250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003047A CL2021003047A1 (es) | 2019-05-23 | 2021-11-18 | Forma cristalina de bromuro de sofpironio y método para su preparación |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220298108A1 (https=) |
| EP (1) | EP3972955A4 (https=) |
| JP (2) | JP6748329B1 (https=) |
| KR (1) | KR20220011671A (https=) |
| CN (1) | CN114008023B (https=) |
| AU (1) | AU2020277881B2 (https=) |
| BR (1) | BR112021023241A2 (https=) |
| CA (1) | CA3139948A1 (https=) |
| CL (1) | CL2021003047A1 (https=) |
| CO (1) | CO2021017456A2 (https=) |
| IL (1) | IL288285B1 (https=) |
| MX (1) | MX2021014163A (https=) |
| MY (1) | MY206154A (https=) |
| PH (1) | PH12021552915A1 (https=) |
| SG (1) | SG11202111678WA (https=) |
| TW (2) | TWI838531B (https=) |
| WO (1) | WO2020235665A1 (https=) |
| ZA (1) | ZA202109514B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3972955A4 (en) * | 2019-05-23 | 2023-07-05 | Kaken Pharmaceutical Co., Ltd. | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND ASSOCIATED METHOD OF PREPARATION |
| EP4213158A1 (en) | 2020-11-13 | 2023-07-19 | Ahead Biocomputing, Co. Ltd | Information processing device, information processing method, recording medium recording information processing program, and information processing system |
| CN115925603B (zh) * | 2022-11-29 | 2025-07-22 | 山东齐都药业有限公司 | 索吡溴铵的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| ATE529399T1 (de) * | 2005-11-10 | 2011-11-15 | Nicholas S Bodor | Sanfte anticholinerge ester |
| ATE529400T1 (de) * | 2005-11-10 | 2011-11-15 | Nicholas S Bodor | Weiche anticholinerge zwitterionen |
| MX357741B (es) * | 2012-07-06 | 2018-07-23 | Laboratorios Senosiain S A De C V Star | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
| US9512166B2 (en) * | 2012-09-05 | 2016-12-06 | Amri Ssci, Llc | Cocrystals of progesterone |
| US20150259283A1 (en) * | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| US10282282B2 (en) * | 2016-06-29 | 2019-05-07 | Synopsys, Inc. | Automated HTTP user flows simulator |
| WO2018026869A1 (en) * | 2016-08-02 | 2018-02-08 | Dermira, Inc. | Processes for making, and methods of using, glycopyrronium compounds |
| EP3972955A4 (en) * | 2019-05-23 | 2023-07-05 | Kaken Pharmaceutical Co., Ltd. | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND ASSOCIATED METHOD OF PREPARATION |
-
2020
- 2020-05-22 EP EP20809754.3A patent/EP3972955A4/en active Pending
- 2020-05-22 TW TW109117164A patent/TWI838531B/zh active
- 2020-05-22 IL IL288285A patent/IL288285B1/en unknown
- 2020-05-22 SG SG11202111678WA patent/SG11202111678WA/en unknown
- 2020-05-22 CA CA3139948A patent/CA3139948A1/en active Pending
- 2020-05-22 JP JP2020089283A patent/JP6748329B1/ja active Active
- 2020-05-22 WO PCT/JP2020/020210 patent/WO2020235665A1/en not_active Ceased
- 2020-05-22 CN CN202080034880.8A patent/CN114008023B/zh active Active
- 2020-05-22 MY MYPI2021006212A patent/MY206154A/en unknown
- 2020-05-22 BR BR112021023241A patent/BR112021023241A2/pt unknown
- 2020-05-22 MX MX2021014163A patent/MX2021014163A/es unknown
- 2020-05-22 AU AU2020277881A patent/AU2020277881B2/en active Active
- 2020-05-22 KR KR1020217041385A patent/KR20220011671A/ko not_active Ceased
- 2020-05-22 TW TW112144978A patent/TWI870116B/zh active
- 2020-05-22 US US17/611,158 patent/US20220298108A1/en active Pending
- 2020-08-06 JP JP2020133620A patent/JP7605598B2/ja active Active
- 2020-11-25 US US17/105,376 patent/US11566000B2/en active Active
- 2020-11-26 PH PH1/2021/552915A patent/PH12021552915A1/en unknown
-
2021
- 2021-06-30 US US17/364,445 patent/US11584715B2/en active Active
- 2021-11-18 CL CL2021003047A patent/CL2021003047A1/es unknown
- 2021-11-24 ZA ZA2021/09514A patent/ZA202109514B/en unknown
- 2021-12-20 CO CONC2021/0017456A patent/CO2021017456A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3139948A1 (en) | 2020-11-26 |
| IL288285B1 (en) | 2026-02-01 |
| CN114008023A (zh) | 2022-02-01 |
| US20210395197A1 (en) | 2021-12-23 |
| AU2020277881B2 (en) | 2025-03-06 |
| CO2021017456A2 (es) | 2022-01-17 |
| WO2020235665A1 (en) | 2020-11-26 |
| MX2021014163A (es) | 2022-01-04 |
| ZA202109514B (en) | 2023-12-20 |
| PH12021552915A1 (en) | 2022-04-04 |
| SG11202111678WA (en) | 2021-11-29 |
| BR112021023241A2 (pt) | 2022-01-04 |
| US20220298108A1 (en) | 2022-09-22 |
| JP7605598B2 (ja) | 2024-12-24 |
| CN114008023B (zh) | 2024-02-09 |
| US11584715B2 (en) | 2023-02-21 |
| EP3972955A1 (en) | 2022-03-30 |
| MY206154A (en) | 2024-12-02 |
| IL288285A (en) | 2022-01-01 |
| AU2020277881A1 (en) | 2021-12-09 |
| JP6748329B1 (ja) | 2020-08-26 |
| TWI870116B (zh) | 2025-01-11 |
| TW202411205A (zh) | 2024-03-16 |
| TWI838531B (zh) | 2024-04-11 |
| US20210171460A1 (en) | 2021-06-10 |
| JP2020189839A (ja) | 2020-11-26 |
| EP3972955A4 (en) | 2023-07-05 |
| JP2020189856A (ja) | 2020-11-26 |
| KR20220011671A (ko) | 2022-01-28 |
| TW202110796A (zh) | 2021-03-16 |
| US11566000B2 (en) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003047A1 (es) | Forma cristalina de bromuro de sofpironio y método para su preparación | |
| PH12021552083A1 (en) | Fused tricyclic compounds useful as anticancer agents | |
| AR134022A2 (es) | Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| MX2020012972A (es) | Combinacion farmaceutica, composicion y preparacion de compuestos que contienen activador de glucocinasa y bloqueador de canales k-atp, metodo de preparacion y uso de los mismos. | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| AR113782A1 (es) | Preparación y almacenamiento de formulaciones de arn liposomal adecuadas para tratamiento | |
| TN2017000524A1 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| AR071788A1 (es) | Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros. | |
| MX2017010062A (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
| WO2017210545A8 (en) | Potassium channel modulators | |
| CY1126141T1 (el) | Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης | |
| AR083484A1 (es) | Mezcla de fosfato para fabricar un cemento de alta resistencia, composicion, suspension de cemento y metodo para fabricar un producto cementoso | |
| PH12021551873A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| AR068187A1 (es) | Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv | |
| PE20141049A1 (es) | Composicion farmaceutica antihipertensiva | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. | |
| PH12018500316A1 (en) | Fumagillol spirocyclic compounds and fused bicyclic compounds and their use as metap2 inhibitors | |
| PH12018501644B1 (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| MX2019010438A (es) | Composicion gomosa con estabilidad mejorada. | |
| WO2018125880A8 (en) | Nrf2 activator | |
| MY209035A (en) | Tricyclic compounds and their use | |
| PH12019500822A1 (en) | Crystalline forms of eravacycline | |
| MX359069B (es) | Sal y formas cristalinas de inhibidor de quinasa tipo polo-4. | |
| MY185235A (en) | New crystalline form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same | |
| MX2021004379A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen. |